全球HIV相关神经认知障碍的患病率与负担:一项Meta分析
该Meta分析纳入123项研究、35,513名HIV感染者,评估HIV相关神经认知障碍(HAND)的全球患病率与负担。HAND总患病率为42.6%,无症状神经认知损害、轻度神经认知障碍和HIV相关痴呆分别为23.5%、13.3%和5.0%。全球估计约16,145,400例HAND病例,其中72%在撒哈拉以南非洲。
要点
- HAND全球总患病率为42.6%,不同诊断标准间无差异。
- CD4最低值<200者HAND患病率45.2%,高于≥200者的37.1%。
- 全球约16,145,400例HAND,72%集中在撒哈拉以南非洲。
核心结论
- 在抗逆转录病毒治疗时代,HIV感染者HAND负担仍高,尤其在撒哈拉以南非洲和拉丁美洲。
- 早期启动ART并维持高CD4细胞计数可能降低HAND患病率和严重程度。
研究设计与样本
- 系统检索PubMed和Embase从1996年1月1日至2020年5月15日的横断面或队列研究,无语言限制。
- 纳入123项研究,涉及32个国家的35,513名HIV感染成人。
- 采用随机效应模型估计HAND的合并患病率。
主要发现
- HAND总患病率为42.6%(95%CI 39.7-45.5),不同诊断标准间无差异。
- 按Frascati标准,无症状神经认知损害患病率23.5%(95%CI 20.3-26.8),轻度神经认知障碍13.3%(95%CI 10.6-16.3),HIV相关痴呆5.0%(95%CI 3.5-6.8)。
- CD4最低值均值/中位数<200组HAND患病率45.2%(95%CI 40.5-49.9),≥200组为37.1%(95%CI 32.7-41.7)。
- 全球估计约16,145,400例(95%CI 15,046,300-17,244,500)HAND病例,其中撒哈拉以南非洲约11,571,200例(95%CI 9,600,000-13,568,000),占72%。
关键数值与推荐
- HAND总患病率42.6%(95%CI 39.7-45.5)。
- 无症状神经认知损害23.5%(95%CI 20.3-26.8),轻度神经认知障碍13.3%(95%CI 10.6-16.3),HIV相关痴呆5.0%(95%CI 3.5-6.8)。
- CD4最低值<200者HAND患病率45.2%(95%CI 40.5-49.9),≥200者37.1%(95%CI 32.7-41.7)。
临床怎么用
- 对HIV感染者应关注HAND筛查,尤其CD4最低值较低者。
- 早期启动ART并维持高CD4细胞计数可能减少HAND发生。
- 在撒哈拉以南非洲和拉丁美洲等资源有限地区需加强HAND监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize the prevalence and burden of HIV-associated neurocognitive disorder (HAND) and assess associated factors in the global population with HIV. METHODS: We searched PubMed and Embase for cross-sectional or cohort studies reporting the prevalence of HAND or its subtypes in HIV-infected adult populations from January 1, 1996, to May 15, 2020, without language restrictions. Two reviewers independently undertook the study selection, data extraction, and quality assessment. We estimated pooled prevalence of HAND by a random effects model and evaluated its overall burden worldwide. RESULTS: Of 5,588 records identified, we included 123 studies involving 35,513 participants from 32 countries. The overall prevalence of HAND was 42.6% (95% confidence interval [CI] 39.7-45.5) and did not differ with respect to diagnostic criteria used. The prevalence of asymptomatic neurocognitive impairment, mild neurocognitive disorder, and HIV-associated dementia were 23.5% (20.3-26.8), 13.3% (10.6-16.3), and 5.0% (3.5-6.8) according to the Frascati criteria, respectively. The prevalence of HAND was significantly associated with the level of CD4 nadir, with a prevalence of HAND higher in low CD4 nadir groups (mean/median CD4 nadir <200 45.2% [40.5-49.9]) vs the high CD4 nadir group (mean/median CD4 nadir ≥200 37.1% [32.7-41.7]). Worldwide, we estimated that there were roughly 16,145,400 (95% CI 15,046,300-17,244,500) cases of HAND in HIV-infected adults, with 72% in sub-Saharan Africa (11,571,200 cases, 95% CI 9,600,000-13,568,000). CONCLUSIONS: Our findings suggest that people living with HIV have a high burden of HAND in the antiretroviral therapy (ART) era, especially in sub-Saharan Africa and Latin America. Earlier initiation of ART and sustained adherence to maintain a high-level CD4 cell count and prevent severe immunosuppression is likely to reduce the prevalence and severity of HAND.
引用
- Wang Y, Liu M, Lu Q, et al. Global prevalence and burden of HIV-associated neurocognitive disorder: A meta-analysis. Neurology. 2020. PMID: 32887786. doi:10.1212/WNL.0000000000010752
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。